Board summary
Key figures
53,878
Registered population
57.0% aged 18–64
23.5%
Aged 65+
ICB 20.0% · England 17.9%
43.2%
In IMD quintile 1
ICB 30.6% · England 21.0%
~20,983
Core20 residents (est.)
Resident basis; registered basis ~23,302 · see page 3
10,182
Hypertension register
+6.52% in 3 yrs · England +5.60%
723
SMI register
40.8% of Lancaster's
1,720
COPD register
Reviews +22.55% in 3 yrs
Forecast to 2030
11,555
Hypertension patients, 2030
+1,373 on today
72.8%
QRISK ≥20% on statins, 2030
+5.17pp over 3 yrs
5.2%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Hypertension blood pressure control trails England.
Hypertension treatment to target is 61.8% against 65.2% in Lancaster and 70.3% in the ICB and England, which may reflect recall gaps.
SMI BMI recording fell over three years.
From 2023 to 2025, SMI BMI recording fell 6.5 pp to 73.3% while England rose +5.1 pp to 82.1%, consistent with review gaps.
Asthma annual review coverage rose sharply.
Asthma review coverage rose +45.2% from 2023 to 2025 (England +4.4%) to 51.4% (England 65.7%), leaving about 2,100 patients unreviewed.
Population, age and ethnicity
Aged 65+ patients form 23.5% of the list, exceeding Lancaster, ICB and England
BAY PCN comprises 53,878 registered patients across a single practice, Bay Medical Group. Patients aged 65+ represent 23.5% of the list (12,665), above Lancaster (21.8%), the ICB (20.0%) and England (17.9%), while aged 0–17 accounts for 19.5% (10,511) and aged 18–64 represents 57.0% (30,702). Census resident data records Gypsy or Irish Traveller background at 0.2% (Lancaster 0.2%, ICB 0.1%, England 0.1%) and Roma at 0.0% (Lancaster 0.1%, ICB 0.1%, England 0.2%); broader ethnicity was not captured. Registered counts differ from resident Census bases, and projected list growth to 2030 is 0.1% under an unverified model.
Age profile
65+: ICB 20.0%, England 17.9%
Older people · falls rows are Lancaster local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Lancaster LA) | 1,840 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 77.5% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 52.0% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Lancaster LA) | 907 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Lancaster LA) | 10.4 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
With 43.2% Core20 share, deprivation exceeds England's 21.0% by 22.2 percentage points
BAY PCN has an average IMD decile of 3.8, below Lancaster (5.4), the ICB (5.0) and England (5.5). Its registered Core20 share is 43.2%, above Lancaster (21.5%), the ICB (30.6%) and England (21.0%). Resident Core20 estimates total 20,983 people, comprising 4,742 aged 0–17, 12,421 aged 18–64, and 3,820 aged 65+. Resident estimates and the single-practice modelled figure (23,302) rest on differing population bases.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
723
SMI register
1.32% recorded prevalence
429
Learning disability register
0.78% recorded prevalence
29
Care homes, 733 beds
In the PCN catchment
9.6%
Provide unpaid care
Lancaster, Census 2021
Recorded severe mental illness prevalence is 1.3% (723 patients) and learning disability is 0.8% (429), both exceeding England (1.0% and 0.6%). The PCN catchment includes 29 care homes (733 beds). Separately, Lancaster district records 9.6% unpaid carers and 9 rough sleepers, which cannot be extrapolated to registered patients.
Severe mental illness: physical health checks
SMI annual BMI recording is 73.3% (England 82.1%), falling 6.5 pp over 2023 to 2025 (England +5.1 pp). BP checks reached 79.6% (England 83.4%) and alcohol recording 69.8% (England 81.8%), consistent with physical-health monitoring gaps.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
10,182
Hypertension register
+6.52%
Register growth, 3 yrs
Lancaster +8.94% · England +5.60%
+2.71pp
BP control, under 80
≤140/90 · +1.66pp aged 80+
+1,373
More patients by 2030
Forecast 11,555 (21.14%)
Hypertension case-finding and control
Hypertension prevalence is 18.6% (10,182 patients), above Lancaster (15.5%), the ICB (17.2%) and England (15.2%). Over 2023 to 2025, patients with a recent blood pressure reading fell 1.7% (England +3.6%) to 84.4% (England 90.0%). Treatment to target is 61.8%, trailing Lancaster (65.2%), the ICB (70.3%) and England (70.3%), with control at 59.0% under age 80 (England 67.8%) and 73.8% aged 80 and over (England 81.2%). Observation periods were not supplied. Blood pressure control trails England across both younger and older cohorts, indicating that prioritising recall and medication titration for patients above target could address this delivery gap.
Lipids and statins
Statin treatment for diabetic patients aged 40 and over without cardiovascular disease is 66.2%, trailing the ICB (71.3%) and England (73.2%), while QRISK 20% or higher lipid therapy is 61.0% (England 63.6%). Fewer at-risk patients receive lipid-lowering therapy than England benchmarks imply, so prioritising primary prevention recall could address this treatment gap.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 113,703 | £2.90 | £1.64 | £1.86 | £329,739 |
| Cardiovascular (all), 2025 | 164,475 | £3.92 | £3.38 | £3.33 | £644,742 |
In 2026, the PCN prescribed 113,703 lipid-modifying items at £2.90 per item, exceeding Lancaster (£2.09), England (£1.86) and the ICB (£1.64), spending £118,251 more than at England's unit cost. With lipid-modifying cost per item above England and ICB benchmarks, reviewing formulary choices and prescribing mix may identify opportunities to align local spend.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+45.24%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
+1.85%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 8.3% (England 6.6%, ICB 7.6%), with 4,289 registered patients. Although annual reviews rose +45.2% over 2023 to 2025 (England +4.4%) to 51.4%, they trail England (65.7%), leaving about 2,100 patients unreviewed. Prescribing in ages 5-19 is 2,660 items per 1,000 (England 1,488), while second-hand smoke recording is 65.3% (England 78.8%). COPD prevalence is 3.1% (England 1.9%), with reviews at 70.1% (England 76.4%).
Cancer register and children's immunisation
Cancer prevalence is 4.3% (2,338 patients), exceeding England (3.8%). In Q1 2025/26, 6-in-1 coverage at 12 months was 80.7% (denominator 119), trailing England (91.0%) by 10.3 pp and sitting 14.3 pp below the 95.0% target. At age 5 (denominator 131), MMR dose 2 was 80.2% (14.8 pp below target) and 4-in-1 booster reached 77.9% (17.1 pp below target). Uptake trailing targets may leave cohorts under-protected.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
52.4%
Lancashire and South Cumbria ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,010
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Lancashire and South Cumbria ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Breast | 86.0% | 85.4% | 6% | 1,561 |
| Prostate | 42.4% | 53.2% | 11% | 1,404 |
| Lung | 31.1% | 33.8% | 15% | 1,374 |
| Bowel | 44.2% | 47.0% | 13% | 1,198 |
| Skin cancer | 86.1% | 87.8% | 21% | 519 |
In 2022, 52.4% of staged cancers across NHS Lancashire and South Cumbria ICB were diagnosed at stage 1 or 2 (4,642 of 8,863 known-stage cancers), below England (55.3%) and 22.6 percentage points below the 75.0% national ambition. Known stage was recorded for 74.6% of registered cancers (8,863 of 11,883). Reaching the 75.0% ambition would require about 2,010 additional early-stage diagnoses annually across the ICB. Locally, BAY PCN records 4.3% cancer prevalence (2,338 patients). Breast screening coverage is 71.1% (England 69.9%), while cervical screening coverage for women aged 25-49 is 66.6% (England 66.8%). These system staging figures describe the wider ICB, not PCN-specific performance.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
In provisional July 2026 figures, University Hospitals of Morecambe Bay NHS Foundation Trust met the 28-day faster diagnosis standard at 78.4% (England 79.3%; ICB 78.4%), while 62-day referral to treatment was 72.4% (157 of 217), 12.6 percentage points below the 85.0% standard (England 71.2%; ICB 73.6%; Lancashire Teaching Hospitals NHS Foundation Trust 75.0%; Blackpool Teaching Hospitals NHS Foundation Trust 67.5%). For diagnostic 6-week waits, the trust recorded 10.4% across all tests (England 23.1%), though Computed Tomography stood at 13.8% (England 9.9%). These figures reflect acute provider and system performance, not PCN-specific waits.
| Pathways within standard (%) | of Morecambe Bay | Blackpool | Lancashire | Lancashire and South Cumbria ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 78.39 | 71.38 | 82.90 | 78.39 | 79.32 |
| 31-day treatment (96%) | 95.22 | 97.96 | 89.43 | 93.62 | 92.50 |
| 62-day referral to treatment (85%) | 72.35 | 67.48 | 75.04 | 73.62 | 71.16 |
| Diagnostic waits over 6 weeks (%) | of Morecambe Bay | Blackpool | Lancashire | England |
|---|---|---|---|---|
| MRI | 4.04 | 21.80 | 2.41 | 21.40 |
| CT | 13.76 | 16.49 | 14.97 | 9.92 |
| Echocardiography | 10.55 | 7.57 | 13.85 | 28.48 |
| Colonoscopy | 0.60 | 13.08 | 0.00 | 30.83 |
| Gastroscopy | 1.45 | 12.47 | 0.00 | 29.02 |
| All 15 DM01 tests | 10.44 | 26.54 | 26.65 | 23.14 |
| Community services activity | Lancashire residents | Lancashire and South Cumbria ICB |
|---|---|---|
| Care contacts | 126,445 | 193,720 |
| Referrals | 20,415 | 29,855 |
| Patients with a contact | 47,320 | 65,335 |
Community services (residents of Lancashire), Jun 2026 (provisional). In provisional June 2026 data, Lancashire residents accounted for 293,090 community care activities, 126,445 care contacts and 47,320 patients with a contact (ICB: 193,720 contacts and 65,335 patients). Adults aged 65+ represented 56.9% of borough contacts (72,000 of 126,445), while children aged 0-18 had 26,665 contacts. Lancashire residents generated 20,415 community referrals across 16,035 patients (ICB: 29,855 referrals). These experimental figures reflect submitting providers, not registered PCN patients.
Practice variation and patient experience
Bay Medical Group achieved 16.5% vaccination QOF points and 43.9% phone access ease
In 2025/26, Bay Medical Group attained 88.2% overall QOF points (England 92.5%) and 97.1% in the clinical domain (England 97.1%). However, vaccination and immunisation domain achievement reached only 16.5% (England 55.2%), while personalised care adjustments across all domains were 10.4% (England 10.0%). Prioritising childhood and adult immunisation delivery could recover lost points.
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Bay Medical Group | 186 | 43.2 | 43.9% | 69.8% | 77.2% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Twelve of 25 tracked trends trailed England, led by declining mental health checks
Over 2023 to 2025, 12 of 25 tracked measures trailed England. Physical health checks for severe mental illness fell: annual BMI recording fell 6.5 pp to 73.3% (England +5.1 pp to 82.1%) and alcohol recording fell 4.8 pp to 69.8% (England +5.4 pp to 81.8%). Conversely, annual reviews showed substantial three-year relative growth: asthma reviews rose +45.2% (England +4.4%) and heart failure reviews rose +18.0% (England +8.7%), though current heart failure review completion remains below England at 69.0% versus 78.5%.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
BMI record (SMI)
Alcohol record (psychosis)
COPD register
BP check (SMI)
Hypertension BP reading
Asthma reviews
COPD reviews
Heart failure reviews
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Lancaster | Asset | PCN | Lancaster |
|---|---|---|---|---|---|
| Care homes (catchment) | 29 (733 beds) | n/a | Schools (catchment) | 22 | n/a |
| Children's centres | 4 | 10 | Places of worship | 28 | 117 |
| Libraries | 1 | 7 | Day centres (VCS) | n/a | 1 |
| Children and young people (VCS) | n/a | 1 | Carers support groups (VCS) | n/a | 2 |
| Primary schools (LA maintained) | 15 | 49 | Primary academies | n/a | 3 |
| Special schools | n/a | 3 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension recall and titration clinics
Hypertension treatment to target is 61.8% across 10,182 patients (Lancaster 65.2%, ICB 70.3%, England 70.3%), 8.5 pp below England; control under age 80 is 59.0% (England 67.8%). Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured annual asthma review recall
Asthma annual review coverage is 51.4% across 4,289 patients (Lancaster 61.0%, ICB 65.0%, England 65.7%), 14.3 pp below England, leaving about 2,100 patients unreviewed. For discussion: Bay Medical Group could expand standardised asthma review templates and offer remote or after-school slots, pairing inhaler checks with second-hand smoke recording. Low cost, quick to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
Combined SMI physical health checks
Across the 723-patient SMI register, annual BMI recording is 73.3% (England 82.1%, difference -8.8 percentage points), alcohol recording is 69.8% (England 81.8%, difference -12.0 percentage points) and BP recording is 79.6% (England 83.4%, difference -3.8 percentage points). Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Targeted Core twenty outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check recall (p4) | SMI register with a BMI recorded in the last 12 months | MHIS · From Harm to Hope | PCN |
| Hypertension review and titration audit (p5) | Last BP reading of patients (<80 yrs with hypertension) in the last 12 months is <= 140/90 mmHg (denominator incl. PCAs) | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Pre-school immunisation catch-up call (p6) | 4-in-1 pre-school booster (DTaP/IPV) coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Cervical screening recall audit (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Telephone routing and queue review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension recall and titration clinics (p12) | Hypertension register · Hypertension: QOF prevalence · Hypertension patients treated to target | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Option 2 · Structured annual asthma review recall (p12) | Asthma register · Asthma: QOF prevalence · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · Combined SMI physical health checks (p12) | Severe mental illness register · Severe mental illness: QOF prevalence · SMI register with a BP check in the last 12 months | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | ICB | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
